Search: WFRF:(Gostner Johanna M.) > Serum neopterin lev...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05429naa a2200541 4500 | |
001 | oai:research.chalmers.se:88be362a-3942-4a7e-a139-f407c3d64f43 | |
003 | SwePub | |
008 | 201220s2020 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/299189 | |
024 | 7 | a https://doi.org/10.1186/s12879-020-05671-72 DOI |
024 | 7 | a https://research.chalmers.se/publication/5210812 URI |
024 | 7 | a https://gup.ub.gu.se/publication/2991892 URI |
040 | a (SwePub)cthd (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Robertson, Josefinau Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xrobej |
245 | 1 0 | a Serum neopterin levels in relation to mild and severe COVID-19 |
264 | c 2020-12-10 | |
264 | 1 | b Springer Science and Business Media LLC,c 2020 |
338 | a electronic2 rdacarrier | |
520 | a Background: The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is rapidly spreading worldwide. There is limited information about prognostic markers that could help clinicians to identify COVID-19 patients with a poor prognosis. Serum levels of the immune activation marker neopterin has shown to be of prognostic value in patients with SARS. The aim of this study was to investigate whether serum neopterin is associated with the severity of COVID-19. Methods: We included 34 patients with confirmed COVID-19 between March 3 and March 30, 2020. Fifteen patients had mild disease and did not require hospitalization, whereas 19 patients developed severe COVID-19 requiring intensive care. Concentrations of serum neopterin, tryptophan, and kynurenine were measured at and repeatedly after inclusion. Results: We found a more than two-fold higher mean concentration of neopterin in severely ill patients (mean value 42.0 nmol/L (SD 18.2)) compared to patients with mild symptoms (16.9 nmol/L (SD 11.0)). All of the severe cases had elevated neopterin concentrations (> 9.1 nmol/L) at the initial sampling with values ranging from 17.2 to 86.7 nmol/L. In comparison, 10 of 15 patients with mild disease had neopterin levels above 9.1 nmol/L, with concentrations in the range from 4.9 to 31.6 nmol/L. Neopterin levels gradually decreased during the course of COVID-19, but severe cases maintained elevated levels for a longer period. Moreover, lower levels of tryptophan and higher levels of kynurenine, indicating an increased tryptophan catabolism, were seen in the group with severe cases. Conclusions: In conclusion, we found that serum neopterin levels are associated with the severity of COVID-19. Our findings suggest that neopterin could be used as a prognostic marker, but further studies are needed to elucidate how it can be used in the clinic. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Anestesi och intensivvård0 (SwePub)302012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Anesthesiology and Intensive Care0 (SwePub)302012 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
653 | a Neopterin | |
653 | a Tryptophan | |
653 | a COVID-19 | |
653 | a Kynurenine | |
653 | a Prognostic markers | |
700 | 1 | a Gostner, Johanna M.u Medizinische Universität Innsbruck,Medical University of Innsbruck4 aut |
700 | 1 | a Nilsson, Staffan,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper,Department of Mathematical Sciences4 aut0 (Swepub:gu)xnista |
700 | 1 | a Andersson, Lars-Magnus,d 1968u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xalarh |
700 | 1 | a Fuchs, D.u Medizinische Universität Innsbruck,Medical University of Innsbruck4 aut |
700 | 1 | a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xgissm |
710 | 2 | a Göteborgs universitetb Institutionen för biomedicin, avdelningen för infektionssjukdomar4 org |
773 | 0 | t BMC Infectious Diseasesd : Springer Science and Business Media LLCg 20:1q 20:1x 1471-2334 |
856 | 4 | u https://research.chalmers.se/publication/521081/file/521081_Fulltext.pdfx primaryx freey FULLTEXT |
856 | 4 | u https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-020-05671-7 |
856 | 4 8 | u https://doi.org/10.1186/s12879-020-05671-7 |
856 | 4 8 | u https://research.chalmers.se/publication/521081 |
856 | 4 8 | u https://gup.ub.gu.se/publication/299189 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.